Document Type

Conference Proceeding

Publication Date


Publication Title

J Am Acad Dermatol


Atopic dermatitis (AD) is an inflammatory skin disease with a prevalence in the United States of approximately 20%/5%–10% in Black or African American children/adults. In 2 phase 3 studies (TRuE-AD1/TRuE-AD2), 1249 patients (≥12 years old, Investigator’s Global Assessment [IGA] score 2/3, 3%–20% affected body surface area [BSA]) were randomized (2:2:1) to twice-daily 0.75% ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream, 1.5% ruxolitinib cream, or vehicle for an 8-week, double-blind vehicle-controlled period, followed by a double-blind long-term safety period (LTS; as-needed treatment; assessments every 4 weeks) up to Week 52. Patients initially randomized to ruxolitinib remained on their regimen during the LTS; patients initially on vehicle were rerandomized to either ruxolitinib strength. During the LTS, patients treated areas with active AD only, stopped treatment 3 days after lesion clearance, and restarted treatment at recurrence. Among self-identifying Black or African American patients in the 0.75%/1.5% ruxolitinib groups for the full study in this pooled analysis (n = 91/n = 97), 53.8%/61.9% achieved clear/almost clear skin (IGA 0/1) at Week 8. From Week 12–52, 55.2%–73.3%/59.3%–78.7% of patients (range) achieved IGA 0/1. Mean affected BSA was 8.6%/8.3% at baseline, 3.8%/3.6% at Week 8, and 1.7%–3.3%/1.3%–2.5% (range of mean values) through Week 52. Over 52 weeks, treatment-emergent adverse events were reported in 59.3%/56.7% of patients; treatment-related adverse events were reported in 4.4%/6.2%. Incidence of application site reactions was low. In summary, the majority of Black or African American patients achieved clear/almost clear skin using ruxolitinib cream monotherapy, which was well tolerated.





First Page




To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.